Simulations Plus Inc. (SLP) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Simulations Plus Inc. (SLP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

28.66

-0.24 (-0.83%)

At close: Jan 14, 2025, 3:59 PM

28.76

0.33%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	24.51
Market Cap	575.95M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.41
PE Ratio (ttm)	69.91
Forward PE	n/a
Analyst	Buy

Ask	29.8
Volume	307,070
Avg. Volume (20D)	250,954
Open	28.99
Previous Close	28.90
Day's Range	27.65 - 28.99
52-Week Range	24.00 - 51.22
Beta	undefined

About SLP

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus...

[Show more]

Industry Medical - Healthcare Information Services

Sector Healthcare

IPO Date Jun 18, 1997

Employees 243

Stock Exchange NASDAQ

Ticker Symbol SLP

Website https://www.simulations-plus.com

Analyst Forecast

According to 7 analyst ratings, the average rating for SLP stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 74.43% from the latest price.

Buy 85.71%

Hold 14.29%

Sell 0.00%

Stock Forecasts

Why Price Moved

6 days ago · Source

-7.17%

Simulations Plus shares are trading lower after Ke... Unlock content with Pro Subscription

2 months ago · Source

-8.89%

Simulations Plus shares are trading lower after the company reported worse-than-expected Q4 revenue results.

News

2 days ago · businesswire.com

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.

2 days ago · businesswire.com

Simulations Plus Supported Development of Every FDA-Approved Drug in 2024

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approved by the U.S. FDA in 2024.

1 week ago · zacks.com

Simulations Plus' Q1 Earnings Lag Estimates, Revenues Surge Y/Y

SLP's fiscal first-quarter performance is driven by healthy revenue growth across its Software segment and contributions from the acquisition of Pro-ficiency.

1 week ago · seekingalpha.com

Simulations Plus, Inc. (SLP) Q1 2025 Earnings Call Transcript

Simulations Plus, Inc. (NASDAQ:SLP ) Q1 2025 Earnings Conference Call January 7, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & ...

1 week ago · zacks.com

Simulations Plus (SLP) Lags Q1 Earnings Estimates

Simulations Plus (SLP) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.10 per share a year ago.

1 week ago · businesswire.com

Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

1 week ago · zacks.com

3 Software Stocks to Keep an Eye on Amid Industry Headwinds

Amid volatile macroeconomic conditions, Computer Software industry participants like ADSK, BB and SLP are well-poised to capitalize on digital transformation and strong adoption of cloud computing sol...

1 week ago · zacks.com

Simulations Plus Gears Up for Q1 Earnings: What's in Store?

SLP's fiscal first quarter performance is likely to have gained from strength in both Software and Services' segments.

4 weeks ago · businesswire.com

Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions...

1 month ago · zacks.com

Wall Street Analysts Predict a 56.99% Upside in Simulations Plus (SLP): Here's What You Should Know

The consensus price target hints at a 57% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est...

1 month ago · zacks.com

Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?

Simulations Plus (SLP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more str...

2 months ago · businesswire.com

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with the University of Connecticut, was awarded a new FDA grant to investigate additional LAI product technologies.

2 months ago · zacks.com

How Much Upside is Left in Simulations Plus (SLP)? Wall Street Analysts Think 77.52%

The consensus price target hints at a 77.5% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...

2 months ago · businesswire.com

Simulations Plus to Participate in the Stephens Annual Investment Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Shawn O'Connor, CEO, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 20, 2024 at 12:00pm ET.

2 months ago · businesswire.com

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, with industry and academic partners, was awarded a new FDA grant to validate new methods for more efficient drug development.

2 months ago · zacks.com

Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth

SLP's fiscal fourth-quarter performance is driven by healthy revenue growth across its software and services business segments.

2 months ago · seekingalpha.com

Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript

2 months ago · zacks.com

Simulations Plus (SLP) Surpasses Q4 Earnings Estimates

Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago.